Phase II study of ARN-6039 in multiple sclerosis patients.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2016
At a glance
- Drugs ARN 6039 (Primary)
- Indications Multiple sclerosis
- Focus Proof of concept; Therapeutic Use
- 09 Jun 2016 New trial record
- 03 Jun 2016 According to Arrien Pharmaceuticals media release, the company hopes to move the Phase I program through this Phase II trial towards the end of the year.